Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2017, Article ID 2736547, 11 pages
https://doi.org/10.1155/2017/2736547
Review Article

Bone Loss Prevention of Bisphosphonates in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Department of Geriatrics, Xinhua Hospital of Shanghai Jiaotong University, School of Medicine, Shanghai 2000092, China

Correspondence should be addressed to Jing Chang; moc.361@hsgnijgnahc and Yanhong Gao; moc.oohay@0102oaghy

Received 27 December 2016; Revised 19 June 2017; Accepted 12 July 2017; Published 21 August 2017

Academic Editor: Yvette Leung

Copyright © 2017 Yan Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. K. Ghishan and P. R. Kiela, “Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases,” American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 300, no. 2, pp. G191–G201, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. C. A. Lima, “Risk factors for osteoporosis in inflammatory bowel disease patients,” World Journal of Gastrointestinal Pathophysiology, vol. 6, no. 4, p. 210, 2015. View at Publisher · View at Google Scholar
  3. M. Dinca, “Evolution of osteopenia in inflammatory bowel disease,” The American Journal of Gastroenterology, vol. 94, no. 5, pp. 1292–1297. View at Publisher · View at Google Scholar
  4. E. Miznerova, T. Hlavaty, T. Koller et al., “The prevalence and risk factors for osteoporosis in patients with inflammatory bowel disease,” Bratislava Medical Journal, vol. 114, no. 08, pp. 439–445, 2013. View at Publisher · View at Google Scholar
  5. C. N. Bernstein, J. F. Blanchard, W. Leslie, A. Wajda, and B. N. Yu, “The incidence of fracture among patients with inflammatory bowel disease: A population-based cohort study,” Annals of Internal Medicine, vol. 133, no. 10, pp. 795–I50, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Card, J. West, R. Hubbard, and R. F. A. Logan, “Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: A population based cohort study,” Gut, vol. 53, no. 2, pp. 251–255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Schulte, A. U. Dignass, K. Mann, and H. Goebell, “Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 4, no. 4, pp. 268–275, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Miheller, K. Lorinczy, and P. L. Lakatos, “Clinical relevance of changes in bone metabolism in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 16, no. 44, pp. 5536–5542, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Kondo, R. Kitazawa, A. Yamaguchi, and S. Kitazawa, “Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels,” Journal of Cellular Biochemistry, vol. 103, no. 1, pp. 335–345, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. D. S. Amarasekara, J. Yu, and J. Rho, “Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases,” Journal of Immunology Research, vol. 2015, Article ID 832127, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Q. Shih, S. R. Targan, and D. McGovern, “Recent advances in IBD pathogenesis: genetics and immunobiology,” Current Gastroenterology Reports, vol. 10, no. 6, pp. 568–575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. G. G. Russell, “Bisphosphonates: the first 40 years,” Bone, vol. 49, no. 1, pp. 2–19, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Y. Y. Leung, A. Y. Y. Ho, T. P. Ip, G. Lee, and A. W. C. Kung, “The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: A randomized placebo-controlled study,” Bone, vol. 36, no. 2, pp. 358–364, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. A. Stoch, K. G. Saag, M. Greenwald et al., “Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: A 12-month randomized, placebo-controlled clinical trial,” Journal of Rheumatology, vol. 36, no. 8, pp. 1705–1714, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. D. M. Black, “Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial,” Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 11, pp. 4118–4124, 2000. View at Publisher · View at Google Scholar
  16. G. A. Wells, A. Cranney, J. Peterson et al., “Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.,” Cochrane database of systematic reviews (Online), no. 1, p. CD001155, 2008. View at Google Scholar · View at Scopus
  17. G. Wells, A. Cranney, J. Peterson et al., “Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women,” Cochrane Database of Systematic Reviews, vol. 23, no. 1, Article ID CD004523, 2008. View at Google Scholar · View at Scopus
  18. C. v. Tirpitz, J. Klaus, J. Brückel et al., “Increase of bone mineral density with sodium fluoride in patients with Crohnʼs disease,” European Journal of Gastroenterology & Hepatology, vol. 12, no. 1, pp. 19–24, 2000. View at Publisher · View at Google Scholar
  19. H. N. de Souza, F. L. Lora, C. A. M. Kulak, N. C. P. Mañas, H. M. B. Amarante, and V. Z. C. Borba, “Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 52, no. 4, pp. 684–691, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Abitbol, K. Briot, C. Roux et al., “A Double-Blind Placebo-Controlled Study of Intravenous Clodronate for Prevention of Steroid-Induced Bone Loss in Inflammatory Bowel Disease,” Clinical Gastroenterology and Hepatology, vol. 5, no. 10, pp. 1184–1189, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Saag, R. Emkey, and T. Schnitzer, “ALENDRONATE AND CORTICOSTEROID-INDUCED OSTEOPOROSIS,” Southern Medical Journal, vol. 91, no. 11, p. 1084, 1998. View at Publisher · View at Google Scholar
  22. J. Klaus, M. Reinshagen, K. Herdt et al., “Bones and Crohn's: No benefit of adding sodium fluoride or ibandronate to calcium and vitamin D,” World Journal of Gastroenterology, vol. 17, no. 3, pp. 334–342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. K. V. Haderslev, L. Tjellesen, H. A. Sorensen, and M. Staun, “Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease,” Gastroenterology, vol. 119, no. 3, pp. 639–646, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. S. A. Bartram, R. T. Peaston, D. J. Rawlings, R. M. Francis, and N. P. Thompson, “A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 18, no. 11-12, pp. 1121–1127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Tirpitz, J. Klaus, and M. Steinkamp, “Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate,” Alimentary pharmacology therapeutics, vol. 17, pp. 807–16, 2003. View at Publisher · View at Google Scholar
  26. S. Palomba, F. Orio Jr., F. Manguso et al., “Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease,” Osteoporosis International, vol. 16, no. 9, pp. 1141–1149, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. J. S. Siffledeen, R. N. Fedorak, K. Siminoski et al., “Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease,” Clinical Gastroenterology and Hepatology, vol. 3, no. 2, pp. 122–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Henderson, N. Hoffman, and R. Prince, “A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease,” American Journal of Gastroenterology, vol. 101, no. 1, pp. 119–123, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Soo, J. Siffledeen, K. Siminoski, B. McQueen, and R. N. Fedorak, “Risedronate improves bone mineral density in Crohn's disease: A two year randomized controlled clinical trial,” Journal of Crohn's and Colitis, vol. 6, no. 7, pp. 777–786, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. A. A. Van Bodegraven, N. Bravenboer, B. I. Witte et al., “Treatment of bone loss in osteopenic patients with Crohn's disease: A double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation,” Gut, vol. 63, no. 9, pp. 1424–1430, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Kitazaki, K. Mitsuyama, J. Masuda et al., “Clinical trial: Comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis,” Alimentary Pharmacology and Therapeutics, vol. 29, no. 4, pp. 424–430, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. “Multiple choice in the management of the menopause: Weighted scores for the answers,” Climacteric, vol. 14, no. 6, pp. 703-704, 2011. View at Publisher · View at Google Scholar
  33. Y. Okada, M. Nawata, S. Nakayamada, K. Saito, and Y. Tanaka, “Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy,” Journal of Rheumatology, vol. 35, no. 11, pp. 2249–2254, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. H. M. Pappa, T. M. Saslowsky, R. Filip-Dhima et al., “Efficacy and harms of nasal calcitonin in improving bone density in young patients with inflammatory bowel disease: A randomized, placebo-controlled, double-blind trial,” American Journal of Gastroenterology, vol. 106, no. 8, pp. 1527–1543, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. S. G. Veerappan, M. Healy, B. Walsh, C. A. O'Morain, J. S. Daly, and B. M. Ryan, “A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients,” European Journal of Gastroenterology and Hepatology, vol. 28, no. 11, pp. 1335–1344, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. B. M. Ryan, M. G. V. M. Russel, L. Schurgers et al., “Effect of antitumour necrosis factor-α therapy on bone turnover in patients with active Crohn's disease: A prospective study,” Alimentary Pharmacology and Therapeutics, vol. 20, no. 8, pp. 851–857, 2004. View at Publisher · View at Google Scholar · View at Scopus